title: Body mass index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men treated with brachytherapy.
abstract: OBJECTIVE
  To examine the relationship between body mass index (BMI) and biochemical recurrence (BCR), cancer-specific (CSS) and overall survival (OS) in men treated with permanent prostate brachytherapy (PPB), as there is limited information on the affect of obesity on treatment outcomes for prostate cancer.
  
  
  METHODS
  In all, 1530 patients with clinically localized prostate cancer who underwent PPB were studied. Clinical and pathological data were retrospectively obtained from medical records. The BMI was classified as normal (< 25 kg/m(2)), overweight (25-30 kg/m(2)) and obese (> or = 30 kg/m(2)). BCR was defined as a rise in PSA levels of > or = 2 ng/mL after the nadir had been reached. The cause of death was determined for each deceased patient. Patients with metastatic prostate cancer who died of any cause were classified as prostate cancer deaths. RESULTS In all, 617 (40%) patients were classified as having a normal weight, 754 (49%) overweight and 159 (10%) were obese. The Kaplan-Meier 8-year risk of BCR (95% confidence interval) was 33.3% (27.2-39.4), 29.2% (23.5-34.9) and 29.3% (12.4-46.2) for patients with a BMI of < 25 kg/m(2), 25-30 kg/m(2) and > or = 30 kg/m(2), respectively. The 8-year CSS was 88.2% (83.1-93.3), 88.6% (83.7-93.5) and 90.6% (79.9-101.4) and the 8-year OS was 70.1% (63.6-76.6), 72.9% (66.6-79.2) and 81.8% (69.3-94.3) for these three groups, respectively. Multivariate proportional hazard regression analyses of BMI and established prognostic factors for BCR confirmed the absence of any prognostic value of BMI on BCR, CSS and OS.
  
  
  CONCLUSIONS
  BMI did not appear to have any prognostic value for BCR, CCS or OS in patients with clinically localized prostate cancer treated with PPB.
authors.affiliation: Department of Urology, University Medical Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands. j.g.h.vanroermund@umcutrecht.nl
authors.forename: Joep G H
authors.initials: JG
authors.lastname: van Roermund
authors.forename: Karel A
authors.initials: KA
authors.lastname: Hinnen
authors.forename: Jan J
authors.initials: JJ
authors.lastname: Battermann
authors.forename: J Alfred
authors.initials: JA
authors.lastname: Witjes
authors.forename: J L H Ruud
authors.initials: JL
authors.lastname: Bosch
authors.forename: Lambertus A
authors.initials: LA
authors.lastname: Kiemeney
authors.forename: Marco
authors.initials: M
authors.lastname: van Vulpen
mesh_terms: D000368:Aged; D015992:Body Mass Index; D001918:Brachytherapy; D004812:Epidemiologic Methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology*; D009765:Obesity / Q000150:complications*; D017430:Prostate-Specific Antigen / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D016896:Treatment Outcome
chemical_list: D017430:Prostate-Specific Antigen